TABLE 3.

Each CCM subject’s lesion type, CCM location, flutriciclamide uptake, and SUVs.

Case #, gender	Type of CCM	Lesion location	Lesion SUV (g/ml) average ± *S.D
Subject #1, M	Multiple (n = 6)	Cerebellum_9_R, Pons, Fusiform_R, Caudate_R, Corpus Callosum, Supp_Motor_Area_R	0.50 ± 0.15
Subject #2, F	Multiple (n = 4)	Cuneus_R, Tail of Caudate Nucleus, Temporal_Sup_R, Frontal_Sup_Orb_R	0.57 ± 0.16
Subject #3, M	Sporadic (n = 1)	Cerebelum_4_5_L, Cerebelum_6_L	0.52
Subject #4, M	Multiple (n = 3)	Temporal_Sup_R, Temporal_Mid_R, Temporal_Inf_R, Post-central_R, Precuneus_L	0.38 ± 0.03
Subject #5, M	Multiple (n = 3)	Pons, Temporal_Mid_L, Frontal_Sup_R, Frontal_Sup_Orb_R, Frontal_Mid_Orb_R, Frontal_Mid_R	0.95 ± 0.21
Average	(n = 17)		0.58 ± 0.23

*S.D denotes standard deviation of the SUV.